X

Trial Profile

A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Topotecan
Indications Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

22 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended as change in timeframe for primary end point from 30 months to 2years 1month.
29 Jun 2022 Status changed from active, no longer recruiting to discontinued.
29 Jul 2019 Planned End Date changed from 20 May 2019 to 20 Aug 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com